Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Wen, Chih Chun ^a,b   Chen, Hui Ming ^b,c   Chen, Swey Shen ^b,d,e   Huang, Li Ting ^b   Chang, Wei Ting ^b,f   Wei, Wen Chi ^b,g   Chou, Li Chen ^a   Arulselvan, Palanisamy ^b   Wu, Jin Bin ^a   Kuo, Sheng Chu ^a   Yang, Ning Sun ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Department of Allergy and Vaccinology   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f PROVIDENCE UNIVERSITY   (Taiwan)

^g NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

2 phenyl 4 quinolone; cancer vaccine; colchicine; dendritic cells; immunogenic cell death

Indexed keywords

2 (3 CHLOROPHENYL) 6,7 METHYLENEDIOXYQUINOLIN 4 ONE; 2 (3 FLUOROPHENYL) 6,7 METHYLENEDIOXYQUINOLIN 4 ONE; 4 QUINOLONE DERIVATIVE; ANTINEOPLASTIC AGENT; CALRETICULIN; CANCER VACCINE; COLCHICINE; DENDRITIC CELL VACCINE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MICROTUBULE DEPOLYMERIZING AGENT; UNCLASSIFIED DRUG; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL LYSATE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DAMAGE ASSOCIATED MOLECULAR PATTERN; DENDRITIC CELL; DRUG EFFICACY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IN VIVO STUDY; INOCULATION; MALE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CYTOLOGY; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL DEATH; CELL LINE, TUMOR; COLCHICINE; DENDRITIC CELLS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; QUINOLONES;

EID: 79959277095     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-44     Document Type: Article

References (66)

1. Cancer immunotherapy by dendritic cells. CJ Melief, Immunity 2008 29 372 383 10.1016/j.immuni.2008.08.004 18799145
2. A fresh look at tumor immunosurveillance and immunotherapy. MJ Smyth DI Godfrey JA Trapani, Nat Immunol 2001 2 293 299 10.1038/86297 11276199 (Pubitemid 33706339)
3. Immunobiology of dendritic cells. J Banchereau F Briere C Caux J Davoust S Lebecque YJ Liu B Pulendran K Palucka, Annu Rev Immunol 2000 18 767 811 10.1146/annurev.immunol.18.1.767 10837075 (Pubitemid 30365397)
4. Dendritic cells and the control of immunity. J Banchereau RM Steinman, Nature 1998 392 245 252 10.1038/32588 9521319 (Pubitemid 28155090)
5. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? S Viaud C Thery S Ploix T Tursz V Lapierre O Lantz L Zitvogel N Chaput, Cancer Res 2010 70 1281 1285 10.1158/0008-5472.CAN-09-3276 20145139
6. DC-based cancer vaccines. E Gilboa, J Clin Invest 2007 117 1195 1203 10.1172/JCI31205 17476349 (Pubitemid 46718404)
7. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. N Casares MO Pequignot A Tesniere F Ghiringhelli S Roux N Chaput E Schmitt A Hamai S Hervas-Stubbs M Obeid,, et al. J Exp Med 2005 202 1691 1701 10.1084/jem.20050915 16365148 (Pubitemid 41815875)
8. Immunological aspects of cancer chemotherapy. L Zitvogel L Apetoh F Ghiringhelli G Kroemer, Nat Rev Immunol 2008 8 59 73 10.1038/nri2216 18097448
9. Immunogenic cancer cell death: a key-lock paradigm. A Tesniere L Apetoh F Ghiringhelli N Joza T Panaretakis O Kepp F Schlemmer L Zitvogel G Kroemer, Curr Opin Immunol 2008 20 504 511 10.1016/j.coi.2008.05.007 18573340
10. Molecular characteristics of immunogenic cancer cell death. A Tesniere T Panaretakis O Kepp L Apetoh F Ghiringhelli L Zitvogel G Kroemer, Cell Death Differ 2008 15 3 12 10.1038/sj.cdd.4402269 18007663 (Pubitemid 350286167)
11. Death, danger, and immunity: an infernal trio. G Kroemer L Zitvogel, Immunol Rev 2007 220 5 7 10.1111/j.1600-065X.2007.00576.x 17979835 (Pubitemid 350045576)
12. Microtubules as a target for anticancer drugs. MA Jordan L Wilson, Nat Rev Cancer 2004 4 253 265 10.1038/nrc1317 15057285 (Pubitemid 38525281)
13. Functional microtubules are required for antigen processing by macrophages and dendritic cells. KK Peachman M Rao DR Palmer M Zidanic W Sun CR Alving SW Rothwell, Immunol Lett 2004 95 13 24 10.1016/j.imlet.2004.05.013 15325793 (Pubitemid 39119895)
14. Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway. RW Jackman MG Rhoads E Cornwell SC Kandarian, Exp Cell Res 2009 315 3242 3249 10.1016/j.yexcr.2009.08.020 19732770
15. Discovery of novel immunostimulants by dendritic-cell-based functional screening. N Mizumoto J Gao H Matsushima Y Ogawa H Tanaka A Takashima, Blood 2005 106 3082 3089 10.1182/blood-2005-03-1161 16002424 (Pubitemid 41565904)
16. Colchicine promotes antigen cross-presentation by murine dendritic cells. N Mizumoto H Tanaka H Matsushima M Vishwanath A Takashima, J Invest Dermatol 2007 127 1543 1546 10.1038/sj.jid.5700699 17301837 (Pubitemid 46762970)
17. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. JY Shin SK Lee CD Kang JS Chung EY Lee SY Seo SY Lee SY Baek BS Kim JB Kim S Yoon, Histol Histopathol 2003 18 435 447 12647794 (Pubitemid 36362061)
18. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. SP Shaha J Tomic Y Shi T Pham P Mero D White L He JL Baryza PA Wender JW Booth DE Spaner, Clin Exp Immunol 2009 158 186 198 10.1111/j.1365-2249.2009.04003.x 19737143
19. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. FO Nestle S Alijagic M Gilliet Y Sun S Grabbe R Dummer G Burg D Schadendorf, Nat Med 1998 4 328 332 10.1038/nm0398-328 9500607 (Pubitemid 28144092)
20. Dendritic cells as therapeutic vaccines against cancer. J Banchereau AK Palucka, Nat Rev Immunol 2005 5 296 306 10.1038/nri1592 15803149 (Pubitemid 40516155)
21. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma. K Aravindaram HH Yu CW Lan PH Wang YH Chen HM Chen H Yagita NS Yang, Gene Ther 2009 16 1329 1339 10.1038/gt.2009.90 19626052
22. Dendritic cell-based cancer gene therapy. EL Smits S Anguille N Cools ZN Berneman VF Van Tendeloo, Hum Gene Ther 2009 20 1106 1118 10.1089/hum.2009.145 19656053
23. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. RS Goldszmid J Idoyaga AI Bravo R Steinman J Mordoh R Wainstok, J Immunol 2003 171 5940 5947 14634105 (Pubitemid 37467212)
24. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. RC Fields K Shimizu JJ Mule, Proc Natl Acad Sci USA 1998 95 9482 9487 10.1073/pnas.95.16.9482 9689106 (Pubitemid 28506257)
25. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. T Schwaab A Schwarzer B Wolf TS Crocenzi JD Seigne NA Crosby BF Cole JL Fisher JC Uhlenhake D Mellinger,, et al. Clin Cancer Res 2009 15 4986 4992 10.1158/1078-0432.CCR-08- 3240 19622576
26. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. P Hatfield AE Merrick E West D O'Donnell P Selby R Vile AA Melcher, J Immunother 2008 31 620 632 10.1097/CJI.0b013e31818213df 18600182
27. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. W Asavaroengchai Y Kotera JJ Mule, Proc Natl Acad Sci USA 2002 99 931 936 10.1073/pnas.022634999 11792864 (Pubitemid 34106613)
28. Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. HC Toh WW Wang WK Chia P Kvistborg L Sun K Teo YP Phoon Y Soe SH Tan SW Hee,, et al. Clin Cancer Res 2009 15 7726 7736 10.1158/1078-0432.CCR-09-1537 19996212
29. Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents. L Li HK Wang SC Kuo TS Wu A Mauger CM Lin E Hamel KH Lee, J Med Chem 1994 37 3400 3407 10.1021/jm00046a025 7932568 (Pubitemid 24325054)
30. The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. LC Chou JS Yang LJ Huang HC Wu CC Lu JH Chiang KT Chen SC Kuo JG Chung, J Gastroenterol 2009 44 1055 1063 10.1007/s00535-009-0111-1 19688288
31. Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. SC Hsu JS Yang CL Kuo C Lo JP Lin TC Hsia JJ Lin KC Lai HM Kuo LJ Huang,, et al. J Orthop Res 2009 27 1637 1644 10.1002/jor.20937 19557855
32. Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4- quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. L Li HK Wang SC Kuo TS Wu D Lednicer CM Lin E Hamel KH Lee, J Med Chem 1994 37 1126 1135 10.1021/jm00034a010 8164254 (Pubitemid 24145373)
33. An effective vaccine strategy protective against antigenically distinct tumor variants. KD Pavelko KL Heckman MJ Hansen LR Pease, Cancer Res 2008 68 2471 2478 10.1158/0008-5472.CAN-07-5937 18381456 (Pubitemid 351521823)
34. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. K Inaba M Inaba N Romani H Aya M Deguchi S Ikehara S Muramatsu RM Steinman, J Exp Med 1992 176 1693 1702 10.1084/jem.176.6.1693 1460426
35. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. AK Patel PN Boyd, J Immunol Methods 1995 184 29 38 10.1016/0022-1759(95)00071-H 7622867
36. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. YC Chen PH Lu SL Pan CM Teng SC Kuo TP Lin YF Ho YC Huang JH Guh, Biochem Pharmacol 2007 74 10 19 10.1016/j.bcp.2007.03. 015 17475221
37. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. SW Wang SL Pan CY Peng DY Huang AC Tsai YL Chang JH Guh SC Kuo KH Lee CM Teng, Cancer Lett 2007 257 87 96 10.1016/j.canlet.2007.07.002 17689859
38. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. L Zitvogel O Kepp L Senovilla L Menger N Chaput G Kroemer, Clin Cancer Res 2010 16 3100 3104 10.1158/1078-0432.CCR-09-2891 20421432
39. Immunogenic and tolerogenic cell death. DR Green T Ferguson L Zitvogel G Kroemer, Nat Rev Immunol 2009 9 353 363 10.1038/nri2545 19365408
40. The dual immunoregulatory roles of stress proteins. AG Pockley M Muthana SK Calderwood, Trends Biochem Sci 2008 33 71 79 10.1016/j.tibs.2007.10.005 18182297
41. Survivin, cancer networks and pathway-directed drug discovery. DC Altieri, Nat Rev Cancer 2008 8 61 70 10.1038/nrc2293 18075512
42. Interleukin-12 and the regulation of innate resistance and adaptive immunity. G Trinchieri, Nat Rev Immunol 2003 3 133 146 10.1038/nri1001 12563297 (Pubitemid 37328691)
43. The regulation of IL-10 production by immune cells. M Saraiva A O'Garra, Nat Rev Immunol 2010 10 170 181 10.1038/nri2711 20154735
44. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. A O'Garra KM Murphy, Nat Immunol 2009 10 929 932 10.1038/ni0909-929 19692989
45. IL-4-mediated fine tuning of IL-12p70 production by human DC. E Guenova T Volz K Sauer S Kaesler MR Muller F Wolbing K Chen C Schwarzler P Brossart M Rocken T Biedermann, Eur J Immunol 2008 38 3138 3149 10.1002/eji.200838463 18924208
46. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. Y Yao W Li MH Kaplan CH Chang, J Exp Med 2005 201 1899 1903 10.1084/jem.20050324 15967820 (Pubitemid 41002926)
47. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. H Hochrein M O'Keeffe T Luft S Vandenabeele RJ Grumont E Maraskovsky K Shortman, J Exp Med 2000 192 823 833 10.1084/jem.192.6.823 10993913
48. Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens. X Zhao A Bose H Komita JL Taylor M Kawabe N Chi L Spokas DB Lowe C Goldbach S Alber,, et al. Mol Ther 2010
49. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. N Tsuda DZ Chang T Mine C Efferson A Garcia-Sastre X Wang S Ferrone CG Ioannides, Cancer Res 2007 67 8378 8387 10.1158/0008-5472.CAN-07-0327 17804754 (Pubitemid 47395177)
50. Altered maturation of dendritic cells by taxol, an anticancer drug. HG Joo, J Vet Sci 2003 4 229 234 14685027
51. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. SW Wang SL Pan YC Huang JH Guh PC Chiang DY Huang SC Kuo KH Lee CM Teng, Mol Cancer Ther 2008 7 350 360 10.1158/1535-7163.MCT-07-2000 18281518
52. Prostate cancer as a model for tumour immunotherapy. CG Drake, Nat Rev Immunol 2010 10 580 593 10.1038/nri2817 20651745
53. A shot at cancer. A Park, Time 2009 174 32 36 39 19769216
54. Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. V Marin-Esteban D Charron C Gelin N Mooney, J Immunother 2010 33 364 370 10.1097/CJI.0b013e3181cd1094 20386470
55. Colchicine is a potent adjuvant for eliciting T cell responses. RG Titus, J Immunol 1991 146 4115 4119 2040793
56. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. JP Hegmans JD Veltman ME Lambers IJ de Vries CG Figdor RW Hendriks HC Hoogsteden BN Lambrecht JG Aerts, Am J Respir Crit Care Med 2010 181 1383 1390 10.1164/rccm.200909-1465OC 20167848
57. Tumor antigen presentation by dendritic cells. TR Petersen N Dickgreber IF Hermans, Crit Rev Immunol 2010 30 345 386 20666707
58. Gene gun delivery systems for cancer vaccine approaches. K Aravindaram NS Yang, Methods Mol Biol 2009 542 167 178 10.1007/978-1-59745-561-9-9 19565902
59. Direct gene transfer and vaccination via skin transfection using a gene gun. CF Kuo JH Wang NS Yang, Methods Mol Med 2002 69 137 147 11987773
60. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. V Staniforth SY Wang LF Shyur NS Yang, J Biol Chem 2004 279 5877 5885 14645256 (Pubitemid 38220620)
61. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. H Feng Y Zeng MW Graner E Katsanis, Blood 2002 100 4108 4115 10.1182/blood-2002-05-1389 12393401 (Pubitemid 35396879)
62. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. TJ Fry JL Shand M Milliron SK Tasian CL Mackall, Cancer Immunol Immunother 2009 58 1257 1264 10.1007/s00262-008-0638-7 19139888
63. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. D Brusa S Garetto G Chiorino M Scatolini E Migliore G Camussi L Matera, Vaccine 2008 26 6422 6432 10.1016/j.vaccine.2008.08.063 18848858
64. Calreticulin exposure dictates the immunogenicity of cancer cell death. M Obeid A Tesniere F Ghiringhelli GM Fimia L Apetoh JL Perfettini M Castedo G Mignot T Panaretakis N Casares,, et al. Nat Med 2007 13 54 61 10.1038/nm1523 17187072 (Pubitemid 46067386)
65. Immunogenic death of colon cancer cells treated with oxaliplatin. A Tesniere F Schlemmer V Boige O Kepp I Martins F Ghiringhelli L Aymeric M Michaud L Apetoh L Barault,, et al. Oncogene 2010 29 482 491 10.1038/onc.2009.356 19881547
66. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. H Zhong B Han IL Tourkova A Lokshin A Rosenbloom MR Shurin GV Shurin, Clin Cancer Res 2007 13 5455 5462 10.1158/1078-0432.CCR-07-0517 17875775 (Pubitemid 47510373).